US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
bioAffinity Technologies, Inc. - Warrant
(NQ:
BIAFW
)
0.5671
+0.1581 (+38.66%)
Delayed Quote
Updated: 9:41 AM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bioAffinity Technologies, Inc. - Warrant
< Previous
1
2
3
4
5
Next >
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
October 09, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
October 08, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
October 08, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
October 06, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
September 30, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
September 22, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
September 17, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
September 09, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 03, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
September 01, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
August 20, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
August 18, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
August 14, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
August 13, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
August 07, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
July 27, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
July 22, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
July 07, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
June 22, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Closing of $3.2 Million Offering
June 18, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
June 17, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
June 16, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
June 02, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
May 27, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
May 12, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
May 08, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
April 28, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
April 14, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
April 07, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
April 01, 2026
From
bioAffinity Technologies, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
